TITLE

Roche: buying up for biotech boost

PUB. DATE
September 2005
SOURCE
PharmaWatch: Cancer;Sep2005, Vol. 4 Issue 9, p17
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the announcement by Roche Pharmaceutical Co. that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies. The acquisition fits in with Roche's therapeutic protein initiative, which has seen the monoclonal antibody products MabThera and Herceptin become key growth drivers and led to Roche's position as the global oncology market leader and, through its majority stake in Genentech, the world's leading biologics manufacturer.
ACCESSION #
19121592

 

Related Articles

  • Roche: buying up for biotech boost.  // PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p14 

    The article report that Roche Holding AG has announced that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology markets. The deal promises to strengthen Roche's drug...

  • Roche: buying up for biotech boost.  // PharmaWatch: Monthly Review;Sep2005, Vol. 4 Issue 9, p46 

    Reports that Roche Pharmaceuticals has signed a deal to acquire Swiss biotech firm GlycArt Biotechnology. Information on the similarities in the business strategy of both the companies; Reference to Roche's previous acquisition of a stake in Genentech Inc.; Focus on Roche's access to GlycArt's...

  • Roche on a Roll; Getting Arius for $190M.  // Bioworld Week;7/28/2008, Vol. 16 Issue 30, p4 

    The article reports on the acquisition of antibody screening company Arius Research Inc. by Roche Holding AG for $189.2 million in Toronto, Ontario. It indicates that the Toronto location would serve as a center for the discovery of innovative biotherapeutics, focusing on oncology and...

  • Opinion: Roche: Piramed acquisition strengthens its oncology and I&I portfolio.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p21 

    The article reports on the plan of Roche to acquire British biotechnology firm Piramed. Roche will buy Piramed Ltd. for $160 million along with a $15 million payment which will be due upon the start of the Phase II clinical trials for the company's oncology program. Piramed's oncology and...

  • Molecular Partners, Roche in Oncology Alliance: $61M Up Front. Sheridan, Cormac // BioWorld Today;12/5/2013, Vol. 24 Issue 233, p1 

    The article reports on a multiproduct oncology discovery alliance between Molecular Partners AG and Roche Holding AG that will combine Molecular's Darpin scaffold technology with Roche's expertise in drug conjugates. Molecular and Roche plan to explore the potential of adding a toxic payload to...

  • FURTHER READING.  // PharmaWatch: Cancer;Jun2006, Vol. 5 Issue 6, p26 

    The article lists reports or news articles about cancer treatment published in several issues of "Datamonitor." Tumor marker testing is described in the report "Cancer Diagnostic Testing World Market," in the January 12, 2006 issue. An outlook for the cancer market in Asia for 2010 is presented...

  • Roche Acquires Therapeutic Human Polyclonals For $56.5M. Morrison, Trista // BioWorld Today;4/3/2007, Vol. 18 Issue 64, p1 

    The article reports on the acquisition of Therapeutic Human Polyclonals Inc. and its antibody-producing transgenic rabbits by F. Hoffman-La Roche Ltd. The acquisition increases the stake of Roche in the antibody market, and it also provides a new approach to the creation of other versions of...

  • In Detail.  // BioPharm International;May2007, Vol. 20 Issue 5, p14 

    The article reports developments of two biotechnology companies, including Roche of Switzerland and Eisai Corp. of North America. Roche has acquired Therapeutic Human Polyclonals (THP) Inc. with the payment of $ 56.5 million for full ownership. On the other hand, Eisai Corp, has acquired...

  • Roche Acquires THP For $56.5M.  // Bioworld Week;4/9/2007, Vol. 15 Issue 15, p3 

    The article reports that F. Hoffman-La Roche Ltd. of Basel, Switzerland, has acquired Therapeutic Human Polyclonals Inc. of Mountain View, California, in the amount of $56.5 million. Entails with the acquisition is Therapeutic's antibody-producing transgenic rabbits. Through the acquisition, it...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics